SequelSEC

Rein Therapeutics, Inc. RNTX

Pharmaceutical Preparations · CIK 0001420565 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2025-12-31
Operating income
-$50.63M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Rein Therapeutics, Inc. (RNTX) reported revenue of $0 and net income of -$49.87M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Rein Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Rein Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$0$0$0$0$0$0$0$0$0$0
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$50.63M-$65.11M-$16.28M-$27.65M-$26.60M-$20.50M-$29.96M-$31.90M-$23.01M-$18.17M
Net income-$49.87M-$62.88M-$15.73M-$27.33M-$26.16M-$27.33M-$29.37M-$31.55M-$22.60M-$18.12M
Research & development$11.03M$14.25M$3.99M$17.97M$17.01M$11.17M$17.66M$18.45M$14.24M$10.28M
Weighted-average diluted sharesshares 25.44Mshares 17.94Mshares 4.60Mshares 4.54Mshares 4.44MUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense-$712.00K-$1.54M$0$0$0$0$0$0$0$0
Diluted EPS$-1.96$-3.51$-3.42$-6.02$-5.89UnavailableUnavailableUnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$10.90M$13.86M$11.36M$9.68M$9.60M$9.33M$12.29M$13.45M$8.77M$7.89M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Rein Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$3.22M$12.86M$17.34M$5.19M$3.60M$7.05M$5.31M$10.64M$11.86M$20.72M
Total assets$24.16M$62.19M$106.01M$22.01M$48.48M$16.34M$26.47M$30.31M$52.69M$22.02M
Current assets$4.33M$13.66M$18.27M$21.87M$48.18M$16.33M$19.55M$21.78M$51.84M$21.07M
Total liabilities$7.24M$7.80M$7.71M$3.38M$4.58M$4.18M$10.42M$10.71M$4.89M$4.08M
Current liabilities$6.18M$5.75M$4.38M$3.38M$4.51M$3.96M$5.84M$5.37M$4.89M$4.07M
Total equity incl. NCI$16.92M$54.39M$98.30M$18.62M$43.90M$12.16M$16.05M$19.60M$47.80M-$111.81M
Temporary (mezzanine) equity$45.00M$45.00M$91.41MUnavailableUnavailableUnavailableUnavailableUnavailable$0$129.74M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Goodwill$6.33M$6.33M$6.33MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$3.98M$911.00K$1.19M$1.72M$1.21M$1.60M$1.45M$1.73M$1.60M$1.97M

Cash flow

Rein Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow-$19.36M-$22.29M-$19.81M-$24.86M-$23.75M-$20.48M-$26.47M-$27.93M-$20.53MUnavailable
Capital expendituresUnavailableUnavailableUnavailableUnavailable$157.00K$5.00K$151.00K$4.42M$142.00KUnavailable
Investing cash flowUnavailable$0$16.20M$26.46M-$35.92M$6.41M-$2.81M$24.69M-$38.91MUnavailable
Financing cash flow$9.76M$17.82M$15.79MUnavailable$55.66M$15.80M$23.96M$2.52M$50.59MUnavailable
Net change in cash-$9.65M-$4.47M$12.12M$1.59M-$4.01M$1.74M-$5.32M-$723.00K-$8.85M$16.95M
Stock-based compensation$2.22M$1.12M$1.19M$2.08M$2.26M$1.89M$2.12M$3.28M$1.75M$688.00K
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortization$1.00K$63.00K$119.00K$169.00K$121.00K$163.00K$155.00K$218.00K$129.00K$232.00K

Derived

Rein Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flowUnavailableUnavailableUnavailableUnavailable-$23.91M-$20.48M-$26.62M-$32.35M-$20.67MUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio0.70x2.38x4.17x6.46x10.69x4.12x3.35x4.05x10.60x5.18x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open RNTX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-26View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-15View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

3 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2025-12-31

Difference 45005000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2024-12-31

Difference 45005000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2023-12-31

Difference 91410000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.